Merck KGaA leadership
Merck KGaA appoints Michael Roemer chairman effective immediately, company announced Nov. 22. Roemer has worked at Merck KGaA for 27 years, and was named vice chairman in 2000. He succeeds Bernhard Scheuble who announced his resignation after 24 years with the company. In addition to serving as chairman, Scheuble also oversaw the pharmaceutical business unit, which will now be run by Elmar Schnee, the company says...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”